Surrozen, Inc./DE (SRZNW) SEC Filings, Feb-May 2026

Surrozen, Inc. Chief Executive Officer Craig C. Parker reported routine equity compensation activity and related tax sales. On May 1, 2026, he exercised 12,500 Restricted Stock Units, each converting into one share of common stock at $0.00, increasing his direct holdings to 21,077 shares.

On May 4, 2026, 4,524 common shares were sold at a weighted average price of $33.3328 per share to cover withholding taxes upon RSU vesting in transactions initiated by the company on his behalf. After these transactions, Parker directly held 16,553 common shares. A remaining RSU award of 12,500 units is scheduled to vest in two equal installments on May 1, 2026 and May 1, 2027.

Surrozen, Inc. reports a Schedule 13G showing Point72-affiliated entities beneficially own 615,957 shares of Common Stock, representing 5.4% of the class as of April 22, 2026.

The filing states Point72 Asset Management, Point72 Capital Advisors Inc., and Steven A. Cohen share voting and dispositive power over these shares through Point72 Associates; Point72 Associates holds the economic interest.

Surrozen, Inc. executive Li Yang reported a charitable stock gift. As Executive Vice President of Research, Yang made a bona fide gift of 1,666 shares of Surrozen common stock on March 31, 2026, with no sale proceeds because gifts are transferred without payment.

After this donation, Yang directly holds 14,425 shares of common stock. The filing also shows indirect ownership of 351 shares held by a daughter and 351 shares held by a son, which are reported as indirect family holdings rather than direct trades in the market.

Surrozen, Inc. is calling a virtual 2026 annual stockholder meeting on May 13, 2026, to vote on key governance items. Stockholders will elect two Class II directors, ratify Ernst & Young LLP as auditor, and cast advisory votes on executive pay and how often future say‑on‑pay votes occur.

Holders of 11,486,707 common shares as of March 18, 2026 may vote online, by phone, mail, or during the live webcast. The proxy details board structure, committee memberships, and 2025 pay for top executives, including total compensation of $2,819,017 for CEO Craig Parker.

Surrozen, Inc. reported open-market share purchases by affiliated TCG Crossover funds. On March 23–24, entities associated with TCG Crossover Fund II and Fund III bought a combined 121,881 shares of Surrozen common stock in multiple open-market transactions at prices around $24.90 and $24.69 per share.

The Form 4 shows these positions as indirect holdings, with the shares held of record by TCG Crossover Fund II, L.P. and TCG Crossover Fund III, L.P. After these buys, the reporting entities disclose indirect ownership levels between 683,218 and 736,554 shares across the noted positions, reinforcing their status as significant, greater-than-10% shareholders.

Surrozen reported a much larger 2025 net loss but ended the year with significantly more cash and a sharper focus on ophthalmology. Net loss widened to $242.0 million, or ($32.37) per share, from $63.6 million, largely due to non-cash losses tied to a 2025 private placement and related tranche and warrant liabilities.

Cash and cash equivalents rose to $89.2 million as of December 31, 2025, up from $34.6 million a year earlier, helped by equity sales and warrant exercises in early 2026. Total 2025 revenue was $3.5 million, down from $10.7 million, while research and development and general and administrative expenses increased to $29.4 million and $16.2 million, respectively. The company advanced retinal programs SZN-8141 and SZN-8143, expects to file an IND for SZN-8141 in the second half of 2026, and earned a $5.0 million milestone from Boehringer Ingelheim under the SZN-413 partnership, which also includes up to $586.5 million in potential future milestones.

Surrozen, Inc. (SRZN) reported insider buying by affiliated investment funds. TCG Crossover Fund II, L.P. and TCG Crossover Fund III, L.P., both 10% holders, executed a series of open-market purchases of Common Stock on March 12–16, 2026, totaling 48,997 shares according to the filing’s transaction summary.

The trades were made at prices between 24.8769 and 24.9857 per share and are reported as indirect holdings. TCG Crossover GP II, LLC and TCG Crossover GP III, LLC act as general partners to the funds, and Chen Yu may be deemed to share voting, investment and dispositive power over these securities.

Surrozen, Inc. executive Li Yang received new equity awards consisting of stock options and restricted stock units. On February 17, 2026, Yang was granted options to purchase 100,950 shares of common stock at an exercise price of $0.00 per share and 100,950 restricted stock units.

The stock options vest over four years in 48 equal monthly installments starting February 1, 2026, conditioned on continued service. The RSUs vest in four equal annual installments beginning February 1, 2026, also subject to continued service. These awards represent direct ownership incentives rather than open-market share purchases.

Williams Charles O reported acquisition or exercise transactions in this Form 4 filing.

Surrozen, Inc. reported that its Chief Operating Officer, Charles O. Williams, received two new equity awards. On February 17, 2026, he was granted employee stock options covering 102,900 shares of common stock at a grant price of $0.00 per share. These option shares vest over four years in 48 equal monthly installments starting February 1, 2026, conditioned on continued service. He was also granted 102,900 restricted stock units, each representing one share of common stock, which vest in four equal annual installments beginning February 1, 2026, also subject to continued service.